Parkinson's disease

Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics

Volumn , Issue , 2005, Pages 561-574

  Goetz, Christopher G ^a   Kompoliti, Katie ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927086031     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544873.039     Document Type: Chapter

References (190)

1. Aarsland, D., Larsen, J. P., Tandberg, E. & Laake, K. (2000). Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J. Am. Geriatr. Soc., 48, 938-42.
2. Aarsland, D., Anderson, K., Larsen, J.P., Lolk, A., Nielsen, H. & Kragh-Sorenson, P. (2001). Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology, 56, 736-6.
3. Adam, D. (2000). Pesticide use linked to Parkinson's disease. Nature, 408, 125.
4. Ahlskog, J. E. & Muenter, M. D. (2001). Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord., 16, 448-58.
5. Andersen, J. K. (2000). What causes the build-up of ubiquitincontaining inclusions in Parkinson's disease? Mech Ageing Dev., 118, 15-22.
6. Araki, I., Kitahara, M., Oida, T. & Kuno, S. (2000). Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J. Urol., 164, 1640-3.
7. Arnulf, I., Bonnet, A. M., Damier, P. et al. (2000b). Hallucinations, REMsleep, and Parkinson's disease:amedicalhypothesis. Neurology, 55, 281-8.
8. Asenbaum, S., Pirker, W., Angelberger, P., Bencsits, G., Pruckmayer, M. & Brucke, T. (1998). [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J. Neural Transm., 105, 1213- 28.
9. Barbeau, A. (1962). The pathogenesis of Parkinson's disease: a new hypothesis. Can.Med. Assoc. J., 87, 802-7.
10. Barbeau, A. & Pourcher, E. (1982). New data on the genetics of Parkinson's disease. Can. J. Neurol. Sci., 9, 53-60.
11. Beal, M. F. (2001). Experimental models of Parkinson's disease.Nat. Rev. Neurosci., 2, 325-34.
12. Benamer, H. T., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. & Grosset, D. G. (2000). Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov. Disord., 15, 692-8.
13. Benedetti, M.D., Bower, J. H., Maraganore, D.M. et al. (2000). Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology, 55, 1350-8.
14. Beyer, M. K., Herlofson, K., Arsland, D. & Larsen, J. P. (2001). Causes of death in a community-based study of Parkinson's disease. Acta Neurol. Scand., 103, 7-11.
15. Birkmayer, W. & Hornikewicz, O. (1961). Der L-dioxyphenylalanin (=L-Dopa) effekt bei der Parkinson-Akinesie. Wien. Klin. Wochenschr., 73, 787-8.
16. Blandini, F., Nappi, G., Tassorelli, C. F. & Martignoni, E. (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol., 62, 63-88.
17. Bordet, R., Broly, F. & Destée, A. (1996). Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Adv. Neurol., 65, 97-100.
18. Brissaud, E. (1895). Lec¸ons sur les Maladies Nerveuses. Paris: Masson.
19. Brooks, D. J. (2000a). PET studies and motor complications in Parkinson's disease. Trends Neurosci., 23 (Suppl 10), S101- 8.
20. Brotchie, J. M. (2000). The neural mechanisms underlying levodopa-induceddyskinesia in Parkinson's disease. Ann.Neurol., 47, S105-12.
21. Buttner, T., Muller, T. & Kuhn, W. (2000). Effects of apomorphine on visual functions in Parkinson's disease. J. Neural. Transm., 107, 87-94.
22. Camicioli, R., Grossmann, S. J., Spencer, P. S., Hudnell, K. & Anger, W. K. (2001). Discriminating mild parkinsonism: methods for epidemiological research. Mov. Disord., 16, 33-40.
23. Carboncini, M. C., Manzoni, D., Strambi, S. et al. (2001). The relation between EMGactivity and kinematic parameters strongly supports a role of the action tremor in parkinsonian bradykinesia. Mov. Disord., 16, 47-57.
24. Chan, P., Tanner, C. M., Jiang, X. & Langston, J.W. (1998). Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology, 50, 513-14.
25. Chan, D. K., Hung, W. T., Wong, A., Hu, E. & Beran, R. G. (2000). Validating a screening questionnaire for parkinsonism in Australia. J. Neurol. Neurosurg. Psychiatry, 69, 117-20.
26. Charcot, J. M. (1879). Lecture V. on paralysis agitans. In Lectures on Diseases of the Nervous system, ed. J. M. Charcot (translator G. Sigerson). Philadelphia: HC Lea.
27. Chase, T. N. & Oh, J. D. (2000). Striatal dopamine- and glutamatemediated dysregulation in experimental parkinsonism. Trends Neurosci., 23(Suppl 10), S86-91.
28. Checkoway, H., Franklin, G. M. & Costa-Mallen, P. (1998). A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology, 50, 1458- 61.
29. Christensen, P. M., Gotzsche, P. C. & Brosen, K. (1998). The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics, 8, 473-9.
30. Clarke, C. E. (1995). Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov. Disord., 10(3), 250-6.
31. Colcher, A. & Simuni, T. (1999). Clinical manifestations of Parkinson's disease.Med. Clin. North Am., 83, 327-47.
32. Colosimo, C. & DeMichele, M. (1999). Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur. J. Neurol., 6, 1-21.
33. Cotzias, G. C., Van Woert, M. H. & Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 276, 374-9.
34. Costa-Mallen, P., Costa, L. G., Smith-Weller, T., Franklin, G. M., Swanson, P. D. & Checkoway, H. (2000). Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism. J. Neurol. Neurosurg. Psychiatry, 69, 535-7.
35. de Jong, G. J., Meerwaldt, J.D. & Schmitz, P. I. M. (1987). Factors that influence the occurrence of response variations in Parkinson's disease. Ann. Neurol., 22, 4-7.
36. De la Fuente-Fernandez, R. (2000). Maternal effect on Parkinson's disease. Ann. Neurol., 48, 782-7.
37. de Rijk, M. C., Tzourio, C., Breteler, M. M. et al. (1997). Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson'sDisease. J. Neurol. Neurosurg. Psychiatry, 62, 10-15.
38. Diederich, N. J., Hilder, C., Goetz, C. G., Keipes, M., Hentges, F. & Metz, H. (1996). Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann. Neurol., 40, 233-4.
39. DiMauro, S. (1993). Mitochondrial involvement in Parkinson's disease. Neurology, 43, 2170-2.
40. Donnan, P. T., Steinke, D. T., Stubbings, C., Davey, P. G. & Mac-Donald, T. M. (2000). Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology, 55, 1785-9.
41. Dujardin, K., Defebvre, L., Grunberg, C., Becquet, E. & Destee, A. (2001). Memory and executive function in sporadic and familial Parkinson's disease. Brain, 124, 89-98.
42. Duvoisin, R. C. (1989). Is there a Parkinson's disease? In Disorders of Movement, ed. N. P.Quinn& P. G. Jenner, London: Academic Press.
43. Dymek, M.P., Atchison, P., Harrell, L. & Marson, D.C.(2001). Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease. Neurology, 56, 17-24.
44. Eidelberg, D., Moeller, J. R., Ishikawa, T. et al. (1995). Early differential diagnosis of Parkinson's disease with 18Ffluorodeoxyglucose and positron emission tomography. Neurology, 45, 1195-2004.
45. Elbaz, A., Manubens-Bertran, J. M., Baldereschi, M. et al. (2000). Parkinson's disease, smoking, and family history. Europarkinson Study Group. J. Neurol., 247, 793-8.
46. Factor, S. A. & Molho, E. S. (2000). Emergency department presentations of patients withParkinson's disease.Am. J.Emerg.Med., 18(2), 209-15.
47. Fenelon, G., Mahieux, F., Huon, R. & Ziegler, M. (2000). Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain, 123, 733-45.
48. Fleming, L., Mann, J. B., Bean, J., Briggle, T. & Sanchez-Ramos, J. R. (1994). Parkinson's disease and brain levels of organochlorine pesticides. Ann. Neurol., 36(Suppl 1), 100-3.
49. Frucht, S. J., Greene, P. E. & Fahn, S. (2000). Sleep disorders in Parkinson's disease: a wake-up call. Mov. Disord., 15, 601-3.
50. Galvin, J. E., Lee, V. M. & Trojanowski, J. Q. (2001). Synucleinopathies: clinical and pathological implications. Arch. Neurol., 58, 186-90.
51. Gao, X. & Dluzen, D. E. (2001). The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res., 892, 63-9.
52. Gerstenbrand, F. & Karamat, E. (1999). Adolf Hitler's Parkinson's disease and an attempt to analyze his personality structure. Eur. J. Neurol., 6, 121-7.
53. Goetz, C. G. (1999). Hallucinations in Parkinson's disease: the clinical syndrome. In Advances in Neurology: Parkinson's Disease, ed. G. M. Stern, vol. 80, pp. 419-23. Philadelphia: Lippincott, Williams & Wilkins.
54. Goetz, C. G. & Stebbins, G. T. (1992). Risk factors for nursing home placement in Parkinson's disease. Ann. Neurol., 32, 250.
55. Goetz, C. G., Lutge, W. & Tanner, C. M. (1986). Autonomic dysfunction in Parkinson's disease. Neurology, 36, 73-5.
56. Goetz, C. G., Tanner, C. M. & Shannon, K. M. (1987). Progression of Parkinson's disease without levodopa. Neurology, 37, 695-8.
57. Goetz, C. G., Burke, P. F., Leurgans, S. et al. (2001). Genetic variation analysis in Parkinson's disease patients with and without hallucinations: case control study. Arch. Neurol., 58, 209-13.
58. Goetz, C. G., Chmura, T. A. & Lanska, D. J. (2001). The history of Parkinson's disease: Part 2 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov. Dis., 16(1), 156-61.
59. Golbe, L. I., Di Iorio, G., Bonavita, V., Miller, D. C. & Duvoisin, R. C. (1990). A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol., 27, 276-82.
60. Gotham, A. M., Brown, R. G. & Marsden, C. D. (1986). Depression in Parkinson's disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry, 49, 381-9.
61. Grasbon-Frodl, E. M., Kosel, S., Riess, O. & Muller, U. (1999). Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson's disease patients. Biochem. Biophys. Res. Commun., 255, 749-52.
62. Gray, P. & Hildebrand, K. (2000). Fall risk factors in Parkinson's disease. J. Neurosci. Nurs., 32, 222-8.
63. Graybiel, A. M. (2000). The basal ganglia. Curr. Biol., 10, R509-11.
64. Greenamyre, J. T. & O'Brien, C. F. (1991). NMDA antagonists in the treatment of Parkinson's disease. Arch. Neurol., 48, 977-81.
65. Greenfield, J. G. & Bosanquet, F. D. (1953). The brain-stem lesions in parkinsonism. J.Neurol.Neurosurg. Psychiatry, 16, 213-26.
66. Greenamyre, J. T., Betarbet, R., Sherer, T. & Panov, A. (2001). Response: Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci., 24, 247.
67. Grunblatt, E., Mandel, S. & Youdim, M. B. (2000). Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann. NY Acad. Sci., 899, 262-73.
68. Haapaniemi, T. H., Ahonen, A., Torniainen, P., Sotaniemi, K. A. & Myllyla, V. V. (2001). [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov. Disord., 16, 124-30.
69. Hartmann, A., Michel, P. P., Troadec, J. D. et al. (2001). Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J.Neurochem., m76, 1785-93.
70. Hauser, R. A., Friedlander, J., Zesiewicz, T. A. et al. (2000). A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol., 23, 75-81.
71. Heikkila, R. E., Manzino, L., Cabbat, F. S. & Duvoisin, R. C. (1984). Protection against the dopaminergic neurotoxicity of MPTPby monoamine oxidase inhibitors. Nature, 311, 467-9.
72. Hilker, R., Klein, C., Ghaemi, M. et al. (2001). Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann. Neurol., 49, 367-76.
73. Hirsch, E. C. (2000). Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann. Neurol., 47, S115-20.
74. Hoehn, M. M. & Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology, 17, 427-42.
75. Holroyd, S., Currie, L. & Wooten, G. F. (2001). Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 70, 734-8.
76. Hoogendijk, W. J., Sommer, I. E., Tissingh, G. & Deeg, D. J. (1998). Depression in Parkinson's disease. The impact of symptom overlap on prevalence. Psychosomatics, 39, 416-21.
77. Horowski, R., Horowski, L., Calne, S. M. & Calne, D. B. (2000). From Wilhelm vonHumboldt toHitler - are prominent people more pronetohave Parkinson's disease? Parkinsonism Relat. Disord., 6, 205-14.
78. Howells, D.W., Porritt, M. J., Wong, J. Y. et al. (2000). Reduced BDNF m RNA expression in the Parkinson's disease substantia nigra. Exp. Neurol., 166, 127-35.
79. Inzelberg, R., Chapman, J., Treves, T. A. et al. (1998). Apolipoprotein E4 in Parkinson's disease and dementia: new data and metaanalysis of published studies. Alzheimer Dis. Assoc.Disord., 12, 45-8.
80. Jacobs, H., Vieregge, A. & Vieregge, P. (2000). Sexuality in young patients with Parkinson's disease: a population based comparison with healthy controls. J.Neurol.Neurosurg.Psychiatry, 69, 550-2.
81. Jankovic, J. (2000). Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin. Neuropharmacol., 23, 252-61.
82. Jankovic, J. & Stacy, M. (1999). Movement disorders. In Textbook of Clinical Neurology, pp. 655-79. Philadelphia:W. B. Saunders.
83. Jankovic, J., McDermott, M., Parkinson Study Group (1990). Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology, 40, 1529-34.
84. Jenner, P. (2001). Parkinson's disease, pesticidesandmitochondrial dysfunction. Trends Neurosci., 24, 245-6.
85. Jimenez del Rio, M. & Velez-Pardo, C. (2000). Molecularmechanism ofmonoaminetoxicity in Parkinson's disease: hypothetical cell death model. Med. Hypotheses, 54, 269-74.
86. Joseph, C., Chassan, J. B. & Koch, M. L. (1978). Levodopa in Parkinson's disease: a long-termappraisal of mortality. Ann. Neurol., 3, 116-18.
87. Kaasinen, V., Någren, K., Hietala, J. et al. (2000). Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology, 54, 1482-7.
88. Karlsen, K. H., Larsen, J. P., Tandberg, E. & Maeland, J. G. (1999). Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 66, 431-5.
89. Karlsen, K. H., Tandberg, E., Aarsland, D. & Larsen, J. P. (2000). Health related quality of life in Parkinson's disease: a prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry, 69, 584-9.
90. Kessler, I. (1978). Parkinson's disease in epidemiologic perspective. Adv. Neurol., 19, 355-84.
91. Khan, N., Graham, E., Dixon, P. et al. (2001). Parkinson's disease is not associated with the combined alphasynuclein/apolipoprotein E susceptibility genotype. Ann. Neurol., 49, 665-8.
92. Klein, C., Schumacher, K., Jacobs, H. et al. (2000). Association studies of Parkinson's disease and parkin polymorphisms. Ann. Neurol., 48, 126-7.
93. Knowlton, B. J., Mangels, J. A. & Squire L. R. (1996). A neostriatal habit learning system in humans. Science, 273, 1399-402.
94. Kobayashi, T., Matsumine, H., Matuda, S. & Mizuno, Y. (1998). Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann. Neurol., 43, 120-3.
95. Kobayashi, T., Wang, M., Hattori, N., Matsumine, H., Kondo, T. & Mizuno, Y. (2000). Exonicdeletionmutationsofthe Parkingene among sporadic patients with Parkinson's disease. Parkinsonism Relat. Disord., 6, 129-31.
96. Kompoliti, K., Comella, C. L., Jaglin, J. A., Leurgans, S., Raman, R. & Goetz, C. G. (2000a). Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology, 55, 1572-5.
97. Kruger, R., Menezes-Saecker, A. M., Schols, L. et al. (2000). Genetic analysis of the alpha2-macroglobulin gene in early- and lateonset Parkinson's disease. Neuroreport, 11, 2439-42.
98. Krüger, R., Kuhn, W., Leenders, K. L. et al. (2001). Familial parkinsonism with synuclein pathology. Neurology, 56, 1355-62.
99. Kuopio, A. M., Marttila, R. J., Helenius, H. & Rinne, U. K. (1999). Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology, 52, 302-8.
100. Kurth, M. C., Tetrud, J. W., Irwin, I., Lyness, W. H. & Langston, J. W. (1993). Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology, 43, 1036-9.
101. Lachenmayer, L. (2000). Parkinson's diseaseandthe ability to drive. J. Neurol., 247 (Suppl 4), IV/28-30.
102. Lang, A. E. & Lozano, A. M. (1998). Parkinson's disease. First of two parts. N. Engl. J.Med., 339, 1044-53.
103. Langston, J. W., Ballard P., Tetrud, J. W. & Irwin, I. (1983). Chronic parkinsonism in humans due to a product of meperidineanalog synthesis. Science, 219, 979-80.
104. Larsen, J. P., Karlsen K. & Tandberg, E. (2000). Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study. Mov. Disord., 15, 826-9.
105. Lee, C. S., Schulzer, M., Mak, E., Hammerstad, J. P., Calne, S. & Calne, D. B. (1995). Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology, 45, 435-9.
106. Leroy E., Anastasopoulos, D., Konitsiotis, S., Lavedan, C. & Polymeropoulos, M. H. (1998). Deletions in the Parkin gene and genetic heterogeneity inaGreekfamilywithearly onsetParkinson's disease. Hum. Genet., 103, 424-7.
107. Levy, R., Vila, M., Herrero, M. T., Faucheux, B., Agid, Y. & Hirsch, E. C. (1995). Striatal expression ofsubstance Pandmethionineenkephalin in genes in patients with Parkinson's disease. Neurosci. Lett., 199, 220-4.
108. Liberini, P., Parola, S., Spano, P. F. & Antonini, L. (2000). Olfaction in Parkinson's disease: methods of assessment and clinical relevance. J. Neurol., 247, 88-96.
109. Litvan, I., Agid, Y., Jankovic, J. et al. (1996). Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 46, 922-30.
110. Litvan, I., MacIntyre, A., Goetz, C. G. et al. (1998). Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodes: a clinicopathologic study. Arch. Neurol., 55, 969-78.
111. LeWitt, P. A., Galloway, M. P., Matson, W. & Milbury, P. (1992). Markers ofdopaminemetabolisminParkinson's disease: the Parkinson Study Group. Neurology, 42, 2111-17.
112. Lou, J. S., Kearns, G., Oken, B., Sexton, G. & Nutt, J. (2001). Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov. Disord., 16, 190-6.
113. Louis, E.D., Marder, K., Coté, L. & Mayeux, R. (1996). Age at death is significantly younger in patients with Parkinson's disease who have dementia. Neurology, 46(Suppl), A377.
114. Lucking, C. B. & Brice, A. (2000). Alpha-synuclein and Parkinson's disease. Cell Mol. Life Sci., 57, 1894-908.
115. Makoff, A. K., Graham, J. M., Arranz, M. J. et al. (2000). Association study of dopamine receptor gene polymorphisms with druginduced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics, 10, 43-8.
116. Marder, K., Logroscino, G., Alfaro, B. et al. (1998a). Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology, 50, 279-81.
117. Menza, M. (2000). The personality associated with Parkinson's disease. Curr. Psychiatry Rep., 2, 421-6.
118. Mesholam, R. I., Moberg, P. J., Mahr, R. N. & Doty, R. L. (1998). Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch. Neurol., 55, 84-90.
119. Messa, C., Volonte, M. A., Fazio, F. et al. (1998). Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur. J. Nucl.Med., 25, 1270-6.
120. Mizuno, Y. K., Sone, N. & Suzuki, K. (1988). Inhibition of mitochondrial respiration by MPTP in mouse brain in vivo. Neurosci. Lett., 91, 349-53.
121. Mizuno, Y., Hattori, N. & Matsumine, H. (1998a) Neurochemical and neurogenetic correlates of Parkinson's disease. J. Neurochem., 71, 893-902.
122. Mizuno, Y., Yoshino, H., Ikebe, S. et al. (1998b). Mitochondrial dysfunction in Parkinson's disease. Ann. Neurol., 44, S99-109.
123. Mizuta, I., Mizuta, E., Yamasaki, S., Kuno, S., Yasuda, M. & Tanaka, C. (2000). Meta-analysis of polymorphism of the catechol-Omethyltransferase gene in relation to the etiology of Parkinson's disease in Japan. Mov. Disord., 15, 1013-14.
124. Muller, J., Wenning, G. K., Jellinger, K., McKee, A., Poewe, W. & Litvan, I. (2000). Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology, q55, 888-91.
125. Munoz, E., Obach, V., Oliva, R. et al. (1999). Alpha1- antichymotrypsin gene polymorphism and susceptibility to Parkinson's disease. Neurology, 52, 297-301.
126. Nicklas, W. J., Vyas, I. & Heikkila, R. E. (1985). Inhibition of NADHlinked oxidation in brain mitochondria by MPTP. Life Sci., 36, 2503-8.
127. Oak, J. N., Oldenhof, J. & Van Tol, H. H. (2000). The dopamine D(4) receptor: one decade of research. Eur. J. Pharmacol., 405, 303-27.
128. Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M. et al. (2000). Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci., 23(Suppl 10), S8-19.
129. Olanow, C. W. (1990). Oxidative reactions in Parkinson's disease. Neurology, 40(Suppl 3), 32-7.
130. Olanow, C.W., Schapira, A. H. & Roth, T. (2000). Waking up to sleep episodes in Parkinson's disease. Mov. Disord., 15, 212-15.
131. Ouchi, Y., Kanno, T., Okada, H. et al. (2001). Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Brain, 124, 784-92.
132. Owen, A. M., Doyon, J., Dagher, A., Sadikot, A. & Evans, A. C. (1998). Abnormal basal ganglia outflow in Parkinson's disease identifiedwith PET. Implications for higher cortical functions. Brain, 121, 949-65.
133. Pahapill, P. A. & Lozano, A. M. (2000). The pedunculopontine nucleus and Parkinson's disease. Brain, 123, 1767-83.
134. Pappert, E. J., Goetz, C. G., Niederman, F. G., Raman, R. & Leurgans, S. (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov. Disord., 14, 117-21.
135. Parkinson, J. (1817). An essay on the shaking palsy. Med. Classics, 10(2), 964-97.
136. Parker, W. D. Jr, Boyson, S. J. & Parks, J. K. (1989). Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol., 26, 719-23.
137. Parkinson Study Group (1993). Effects of tocopherol and deprenyl on the progress disability in early Parkinson's disease. N. Engl. J.Med., 328, 17.
138. Payami, H., Lee, N., Zareparsi, S. et al. (2001). Parkinson's disease, CYP2D6 polymorphism, and age. Neurology, 56, 1363-70.
139. Pezzoli, G., Canesi, M., Antonini, A. et al. (2000). Hydrocarbonexposure and Parkinson's disease. Neurology, 55, 667-73.
140. Piccini, P., Weeks, R. A. & Brooks, D. J. (1997). Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol., 42, 720-6.
141. Ploix, C. & Spier, A. D. (2001). Fighting Bax: towards a Parkinson's disease therapy. Trends Neurosci., 24, 255.
142. Poewe, W. H. & Wenning, G. K. (1998). The natural history of Parkinson's disease. Ann. Neurol., 44, S1-9.
143. Polymeropoulos, M. H., Lavedan, C., Leroy, E. et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-7.
144. Preux, P. M., Condet, A., Anglade, C. et al. (2000). Parkinson's disease and environmental factors.Matched case-control study in the Limousin region, France. Neuroepidemiology, 19, 333-7.
145. Racette, B. A., McGee-Minnich, L., Moerlein, S. M., Mink, J. W., Videen, T. O. & Permutter, J. S. (2000). Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology, 56, 8-13.
146. Rajput, A. H. (1993). Environmental causation of Parkinson's disease. Arch. Neurol., 50, 651-2.
147. Razmy, A. & Shapiro, C. M. (2000). Interactions of sleep and Parkinson's disease. Semin. Clin. Neuropsychiatry, 5(1), 20-32.
148. Reider, C. R. & Hubble, J. P. (2000). Test-retest reliability of an epidemiolgical instrument for Parkinson's disease. J. Clin. Epidemiol., 53, 863-5.
149. Richardson, P. J. (2001). The adenosine A2A receptor of the basal ganglia. J. Physiol., 523, 284.
150. Roberts, S. (1997). James Parkinson 1755-1824; From Apothecary to General Practitioner. London: Roy. Soc.Med. Press.
151. Rodriquez, M., Abdala, P. & Obeso, J. A. (2000). Excitatory responses in the 'direct' striatonigral pathway: effect of nigrostriatal lesion. Mov. Disord., 15, 795-803.
152. Roos, R. A. C., Jongen, J. C. F. & van der Velde, E. A. (1996). Clinical course of patients with Parkinson's disease. Mov. Disord., 11, 236-42.
153. Sato, Y., Kaji, M., Tsuru, T. & Oizumi, K. (2001). Risk factors for hip fracture among elderly patients with Parkinson's disease. J. Neurol. Sci., 182, 89-93.
154. Saha, A. R., Ninkina, N. N., Hanger, D. P., Anderton, B. H., Davies, A. M. & Buchman, V. L. (2000). Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci., 12, 3073-7.
155. Schoenberg, B. S., Osentokun, B. O., Adeuja, A. O. G. et al. (1988). Comparison of the prevalence of Parkinson's disease in black populations in rural United States and in rural Nigeria: door to door community studies. Neurology, 38, 645-6.
156. Schrag, A., Ben-Shlomo, Y., Brown, R., Marsden, C. D. & Quinn, N. (1998). Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov. Disord., 13, 885-94.
157. Schrag, A., Jahanshahi, M. & Quinn, N.(2000). Howdoes Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord., 15, 1112-18.
158. Schuh, L. A. & Bennett, J. P. (1993). Suppression of dyskinesias in advanced Parkinson's disease. Neurology, 43, 1545-50.
159. Sealfon, S. C. & Olanow, C. W. (2000). Dopamine receptors: from structure to behavior. Trends Neurosci., 23(Suppl 10), S34-40.
160. Shashidharan, P., Good, P.F., Hsu, A., Perl, D.P., Brin, M.F. & Olanow, C.W. (2000). Torsin A accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res., 877, 379-81.
161. Siegel, G. J. & Chauhan, N. B. (2000). Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Rev., 33, 199-227.
162. Smith, Y. & Kieval, J. Z. (2000). Anatomy of the dopamine system in the basal ganglia. Trends Neurosci., 23(Suppl 10), S28-33.
163. Speelman, J. D. & Bosch, D. A. (1998). Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective. Mov. Disord., 13, 582-8.
164. Spira, P. J., Sharpe, D. M., Halliday G., Cavanagh, J. & Nicholson, G. A. (2001). Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol., 49, 313-19.
165. Starkstein, S. E., Petracca, G., Chemerinski, E. et al. (1998). Depression in classic versus akinetic-rigid Parkinson's disease. Mov. Disord., 13, 29-33.
166. Tan, E. K., Khajavi, M., Thornby, J. I., Nagamitsu, S., Jankovic, J. & Ashizawa, T. (2000). Variability and validity of polymorphism association studies in Parkinson's disease. Neurology, 55, 533-8.
167. Tandberg, E., Larsen, J. P. & Karlsen, K. (1998). A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord., 13, 895-9.
168. Tanner, C. M. & Aston, D. A. (2000). Epidemiology of Parkinson's disease and akinetic syndromes. Curr. Opin. Neurol., 13, 427-30.
169. Tanner, C. M., Chen, B., Wang, W. et al. (1989). Environmental factors and Parkinson's disease: a case-control study in China. Neurology, 39, 660-3.
170. Tanner, C. M., Ottman, R., Goldman, S. M. et al. (1999). Parkinson's disease in twins: an etiologic study. J. Am. Med. Assoc., 281, 341-6.
171. Tassin, J., Durr, A., deBroucker, T. et al. (1998). Chromosome 6- linked autosomal recessive early-onset Parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family. The French Parkinson's Disease Genetics
172. Study Group, and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Am. J. Hum. Genet., 63, 88-94.
173. Tatton, N. A. (2000). Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol., 166, 29-43.
174. Tissingh, G., Berendse, H. W., Bergmans, P. et al. (2001). Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov. Disord., 16, 41-6.
175. Torstenson, R., Hartvig, P., Langstrom, B., Westerberg, G. & Tedroff, J. (1997). Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann. Neurol., 41, 334-40.
176. Tsuneoka, Y., Matsuo, Y., Ichikawa, Y. & Watanabe, Y. (1998). Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease. Metabolism, 47, 94-6.
177. Tuchsen, F. & Jensen, A. A. (2000). Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. Scand. J.Work Environ. Hlth, 26, 359-62.
178. Turnbull, S., Tabner, B. J., El-Agnaf, O. M., Moore, S., Davies, Y. & Allsop, D. (2001). Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol.Med., 30, 1163-70.
179. Uitti, R. J., Ahlskog, J. E., Maraganore, D. M. et al. (1993). Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County project. Neurology, 43, 1918-26.
180. Vila, M., Jackson-Lewis, V.V., Vukosavic, S. et al. (2001). Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl Acad. Sci., USA, 98, 2837-42.
181. Vingerhoets, F. J., Schulzer M., Calne, D. B. & Snow, B. J. (1997). Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol., 41, 58-64.
182. Volkow, N. D., Wang, G. J., Fowler, J. S. et al. (1998). Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol., 44, 143-7.
183. Wang, W. W., Khajavi, M., Patel, B. J., Beach J. & Jankovic, J. (1998). The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson's disease in non-Greek and/or Italian populations. Arch. Neurol., 55, 1521-3.
184. Wang, M., Hattori, N., Matsumine, H. et al. (1999). Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann. Neurol., 45, 655-8.
185. Weiner, W. J. & Lang, A. E. (1989). Movement Disorders. New York: Futura Publ.
186. Wilhelmsen, K., Mirel, D., Marder, K. et al. (1997). Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann. Neurol., 41, 813-17.
187. Wooten, M. P. & Jankovic, J. (1992). Movement disorders. In Prognosis of Neurological Disorders, ed. R.W. Evans, D. S. Baskin & F. M. Yatsu. New York: Oxford Univ. Press.
188. Wooten, G. F., Currie, L. J., Bennett, J. P., Harrison, M. B., Trugman, J. M. & Parker, W. D. Jr. (1997). Maternal inheritance in Parkinson's disease. Ann. Neurol., 41, 265-8.
189. Youdim, M.B. H., Ben-Shachar, D. & Riederer, P. (1993). Thepossible role of iron in the etiopathology of Parkinson's disease. Mov. Disord., 8(Suppl 1), 1-12.
190. Zareparsi, S., Kay, J., Camicioli, R. et al. (1998). Analysis of the alpha-synuclein G209A mutation in familial Parkinson's disease. Lancet, 351, 37-8.